Companies partner on wearable apomorphine injection system
Serina Therapeutics has partnered with Enable Injections to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced…
Articles by Andrea Lobo
Apomorphine oral spray safe, efficient in Parkinson’s, study finds
An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A…
Targeting specific alpha-synuclein region may thwart toxic aggregation
A region in the alpha-synuclein protein has been identified as a possible target for inhibiting the conversion of oligomers —…
Aspen wins $8M to advance Parkinson’s stem cell therapy
Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem…
Increasing zinc transporter may be Parkinson’s therapeutic target
Enhancing mechanisms associated with the degradation of misfolded proteins at the proteasome, that is, cellular structures where these proteins are…
First patients enrolled in pivotal trial of light therapy for Parkinson’s
The first 25 patients have been enrolled in a Phase 3 trial that’s testing the light-based, at-home therapy device called…
Protein-like polymer may limit oxidative stress, protect nerve cells
A newly developed molecule showed an ability in lab studies to activate antioxidant responses in brain cells by altering how…
Early efficacy data from buntanetap trial delayed, now expected in June
Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is…
Method generates dopaminergic neurons lost in Parkinson’s disease
Researchers in Canada have developed a new method to generate functional dopaminergic neurons, the dopamine-producing nerve cells lost in Parkinson’s…
Cerevance adds $47M in funding, will start CVN424 Phase 3 trial
After adding $47 million in new funding, Cerevance is planning to launch a Phase 3 clinical trial to test its…